Linapride 5 Tablet contains Linagliptin 5 mg, a potent and selective dipeptidyl peptidase-4 (DPP-4) inhibitor indicated for the management of type 2 diabetes mellitus. Linagliptin works by enhancing the incretin system, which increases insulin secretion and decreases glucagon release in a glucose-dependent manner, thereby improving glycemic control without causing significant hypoglycemia. This medication is typically prescribed as an adjunct to diet and exercise to achieve better blood glucose regulation in adults with type 2 diabetes, either as monotherapy or in combination with other antidiabetic agents such as metformin or sulfonylureas. Linapride 5 Tablet is characterized by its once-daily oral dosing, favorable safety profile, and minimal risk of weight gain. It is contraindicated in patients with type 1 diabetes or diabetic ketoacidosis and should be used with caution in individuals with renal or hepatic impairment. Common adverse effects may include nasopharyngitis, headache, and upper respiratory tract infections, though these are generally mild and transient. Regular monitoring of blood glucose levels and periodic assessment of renal function are recommended during therapy. Linapride 5 Tablet offers an effective and well-tolerated option for optimizing glycemic control in type 2 diabetes management.